WSE:PCR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. More Details


Snowflake Analysis

Second-rate dividend payer with imperfect balance sheet.


Similar Companies

Share Price & News

How has PCC Rokita's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCR is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PCR's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

9.6%

PCR

2.0%

PL Chemicals

-0.9%

PL Market


1 Year Return

21.2%

PCR

9.6%

PL Chemicals

0.4%

PL Market

Return vs Industry: PCR exceeded the Polish Chemicals industry which returned 8.2% over the past year.

Return vs Market: PCR exceeded the Polish Market which returned 0.3% over the past year.


Shareholder returns

PCRIndustryMarket
7 Day9.6%2.0%-0.9%
30 Day23.1%10.8%2.5%
90 Day36.1%17.9%16.0%
1 Year30.3%21.2%11.7%9.6%1.3%0.4%
3 Year-30.1%-45.1%-34.6%-40.9%-13.3%-18.6%
5 Year108.1%39.8%-45.0%-52.0%21.6%7.8%

Long-Term Price Volatility Vs. Market

How volatile is PCC Rokita's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PCC Rokita undervalued compared to its fair value and its price relative to the market?

16.73x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PCR (PLN61.8) is trading above our estimate of fair value (PLN26.08)

Significantly Below Fair Value: PCR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PCR is poor value based on its PE Ratio (16.7x) compared to the PL Chemicals industry average (15.6x).

PE vs Market: PCR is poor value based on its PE Ratio (16.7x) compared to the Polish market (13.7x).


Price to Earnings Growth Ratio

PEG Ratio: PCR is poor value based on its PEG Ratio (4.8x)


Price to Book Ratio

PB vs Industry: PCR is overvalued based on its PB Ratio (1.7x) compared to the PL Chemicals industry average (0.9x).


Next Steps

Future Growth

How is PCC Rokita forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

3.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCR's forecast earnings growth (3.5% per year) is above the savings rate (2.7%).

Earnings vs Market: PCR's earnings (3.5% per year) are forecast to grow slower than the Polish market (18% per year).

High Growth Earnings: PCR's earnings are forecast to grow, but not significantly.

Revenue vs Market: PCR's revenue (3.2% per year) is forecast to grow slower than the Polish market (6% per year).

High Growth Revenue: PCR's revenue (3.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCR's Return on Equity is forecast to be low in 3 years time (8.4%).


Next Steps

Past Performance

How has PCC Rokita performed over the past 5 years?

-2.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCR has high quality earnings.

Growing Profit Margin: PCR's current net profit margins (5.2%) are lower than last year (9.5%).


Past Earnings Growth Analysis

Earnings Trend: PCR's earnings have declined by 2.1% per year over the past 5 years.

Accelerating Growth: PCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PCR had negative earnings growth (-49.2%) over the past year, making it difficult to compare to the Chemicals industry average (-1.4%).


Return on Equity

High ROE: PCR's Return on Equity (10.1%) is considered low.


Next Steps

Financial Health

How is PCC Rokita's financial position?


Financial Position Analysis

Short Term Liabilities: PCR's short term assets (PLN348.3M) do not cover its short term liabilities (PLN374.1M).

Long Term Liabilities: PCR's short term assets (PLN348.3M) do not cover its long term liabilities (PLN821.8M).


Debt to Equity History and Analysis

Debt Level: PCR's debt to equity ratio (98.9%) is considered high.

Reducing Debt: PCR's debt to equity ratio has increased from 68.6% to 98.9% over the past 5 years.

Debt Coverage: PCR's debt is well covered by operating cash flow (47.3%).

Interest Coverage: PCR's interest payments on its debt are well covered by EBIT (5.8x coverage).


Balance Sheet


Next Steps

Dividend

What is PCC Rokita current dividend yield, its reliability and sustainability?

5.52%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PCR's dividend (5.52%) is higher than the bottom 25% of dividend payers in the Polish market (1.58%).

High Dividend: PCR's dividend (5.52%) is in the top 25% of dividend payers in the Polish market (5.13%)


Stability and Growth of Payments

Stable Dividend: PCR has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: PCR has only been paying a dividend for 6 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (92.3%), PCR's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PCR's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

zł4m

CEO Compensation


CEO

Wieslaw Klimkowski

no data

Tenure

zł3,948,000

Compensation

Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski serves as President of the Management Board and Director of Investor Superv...


CEO Compensation Analysis

Compensation vs Market: Wieslaw's total compensation ($USD1.06M) is above average for companies of similar size in the Polish market ($USD385.84K).

Compensation vs Earnings: Wieslaw's compensation has been consistent with company performance over the past year.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PCC Rokita SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PCC Rokita SA
  • Ticker: PCR
  • Exchange: WSE
  • Founded: NaN
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: zł1.211b
  • Shares outstanding: 19.85m
  • Website: https://www.pcc.rokita.pl

Number of Employees


Location

  • PCC Rokita SA
  • ul. Sienkiewicza 4
  • Brzeg Dolny
  • 56-120
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCRWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNJun 2014
0QVXLSE (London Stock Exchange)YesBearer SharesGBPLNJun 2014

Biography

PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. The company offers chloralkali, raw materials, and intermediates; polyurethanes; specialty products; and surfacta...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/22 18:03
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.